Returning to the business itself, although it produces pharmaceuticals for a vast range of medical conditions, the acquisition of EUSA has accelerated the group\u2019s focus on rare diseases. \u201cThe backing of a global pharmaceutical company with an established reputation like Recordati\u2019s is hugely exciting for everyone at EUSA,\u201d recalls Jonathan. \u201cIt gave us increased stability, and an ability to invest in our products and expand into new global markets.<\/p>\n
![\"acquisitions](\"https:\/\/manufacturing-today.com\/wp-content\/uploads\/sites\/4\/2023\/06\/acquisitions-1-300x212.png\")
<\/p>\n
\u201cRecordati has accepted and welcomed EUSA on board, with our teams and management smoothly adapting to new structures,\u201d he continues. \u201cI believe that we have added value to the Recordati family, and we are all pulling together to achieve our common goal \u2013 to continually improve our products to best serve our patients.\u201d<\/p>\n
\u201cI strongly agree,\u201d replies Roberto. \u201cThe former EUSA has a high level of competence and experience that we didn\u2019t want to lose through the acquisition process. The combination of different experiences and professional pathways contributes to a better result compared to what the two companies would have achieved independently.\u201d<\/p>\n
Nowhere is this fusion of resources more valuable than in producing pharmaceuticals for rare diseases. The acquisition of EUSA has incorporated its expertise on rare conditions and oncology into Recordati\u2019s reputable portfolio. Defined as a condition affecting fewer than five individuals per 10,000 people in Europe, or fewer than 200,000 Americans in the US, rare diseases are typically under-researched.<\/p>\n
Advanced treatment options<\/strong><\/p>\n However, the group\u2019s subsidiary, Recordati Rare Diseases, is one of the most research-active companies in its field, continuously striving to uncover opportunities that address gaps in healthcare. Believing that every individual has the right to effective treatments, it focuses on helping people with few or no available options. It is particularly passionate about the fight against cancer, providing physicians and patients with advanced treatment options and supportive care products. At a practical level, a new, direct distribution and packaging system enables Recordati Rare Diseases to deliver small quantities of specialist products across the globe, often with short notice.<\/p>\n On the topic of acquisition, Recordati also obtained a rare disease product from Novartis in 2019, which has enabled it to operate a unique production technique in Basel, Switzerland, based on a patent held by Novartis. \u201cWe gained the technology to produce specific rare diseases pharmaceuticals, which uses methanol to slowly release<\/p>\n microparticles,\u201d Roberto explains. \u201cWe also took over the manufacturing plant within the Novartis campus, which has enabled us to continue providing patients with these treatments in exactly the same way as before.\u201d<\/p>\n Improving lives<\/strong><\/p>\n Although the business is experiencing growth and success with its recent acquisitions, it hasn\u2019t necessarily been an easy ride. \u201cFollowing the extremely difficult global events of COVID-19 and the war in Ukraine, the healthcare and pharmaceutical industries are experiencing a challenging and ever-changing environment,\u201d states Roberto. \u201cThe behavior and attitude from patients, healthcare providers, and customers changed during the pandemic. Then, the outbreak of war in Ukraine consolidated these changed attitudes, as well as having a huge impact on our supply chain.<\/p>\n \u201cThe pandemic caused a scarcity of products, components, and specific materials for a long period, which forced all health and pharmaceutical companies, not just Recordati, to adapt themselves and independently manage the production supply chain,\u201d he continues. \u201cWe were extremely proactive and came up with clever, creative ways to manage production, as our major priority is to ensure patients can always get the products they need, available in good time, and with the high-quality standards they are accustomed to.\u201d<\/p>\n Jonathan shares Roberto\u2019s views on the supply chain: \u201cComponents that would previously take three-to-six months were taking 18 months, or even longer, to arrive. Part of this was due to the demand that mass COVID-19 vaccine production placed on available materials in the supply chain. On the other hand, vaccine production shed a positive light on the pharmaceutical industry as a whole. People began to appreciate and value the crucial role of the industry in wider society, especially as countries began to reopen after the pandemic!\u201d<\/p>\n Fernando adds, \u201cFrom the manufacturing point of view, in order to mitigate potential future supply issues, we are currently running numerous projects to enhance efficiency and increase our service levels. Overall, the main objective is to continue being a reliable, trustworthy partner for our portfolio of customers and therefore ultimately our patients.\u201d<\/p>\n Moving forward, the company\u2019s goals for the future are not driven by profits or numbers, but instead driven by people. \u201cThe major goal is to ensure that our patients are not going to suffer from our lack of supply or product availability,\u201d says Roberto. \u201cAs with any other company, we must ensure we can generate enough contribution to sustain all our current activities. In terms of future investment, this will be guided by our patients and how we can further improve their lives.\u201d<\/p>\n![\"\"](\"https:\/\/manufacturing-today.com\/wp-content\/uploads\/sites\/4\/2023\/06\/acquisitions-2.png\")
<\/p>\n